Ionis Pharmaceuticals
Market Cap
US$8.5b
Last Updated
2020/02/16 23:44 UTC
Data Sources
Company Financials +
Executive Summary
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States.
Rewards
Risk Analysis
Snowflake Analysis
Excellent balance sheet with proven track record.
Similar Companies
Share Price & News
How has Ionis Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IONS has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-0.6%
IONS
-0.5%
US Biotechs
1.5%
US Market
1 Year Return
2.0%
IONS
11.0%
US Biotechs
20.1%
US Market
Return vs Industry: IONS underperformed the US Biotechs industry which returned 11% over the past year.
Return vs Market: IONS underperformed the US Market which returned 20.1% over the past year.
Shareholder returns
| IONS | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.6% | -0.5% | 1.5% |
| 30 Day | 0% | 0.6% | 1.4% |
| 90 Day | 4.1% | 9.3% | 8.7% |
| 1 Year | 2.0%2.0% | 12.0%11.0% | 22.7%20.1% |
| 3 Year | 28.1%28.1% | 16.9%13.6% | 50.1%40.5% |
| 5 Year | -10.3%-10.3% | -1.5%-6.2% | 73.1%54.1% |
Price Volatility Vs. Market
How volatile is Ionis Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
11 hours ago | Simply Wall St
Calculating The Fair Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)4 weeks ago | Simply Wall St
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Delivered A Better ROE Than Its Industry1 month ago | Simply Wall St
Ionis Pharmaceuticals (NASDAQ:IONS) Shareholders Have Enjoyed A 26% Share Price GainValuation
Is Ionis Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
0.5%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: IONS ($60.13) is trading below our estimate of fair value ($60.46)
Significantly Below Fair Value: IONS is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: IONS is poor value based on its PE Ratio (19.4x) compared to the Biotechs industry average (19.2x).
PE vs Market: IONS is poor value based on its PE Ratio (19.4x) compared to the US market (18.4x).
Price to Earnings Growth Ratio
PEG Ratio: IONS is poor value based on its PEG Ratio (1.2x)
Price to Book Ratio
PB vs Industry: IONS is overvalued based on its PB Ratio (6.3x) compared to the US Biotechs industry average (3.2x).
Next Steps
Future Growth
How is Ionis Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?
15.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IONS's forecast earnings growth (15.5% per year) is above the savings rate (1.7%).
Earnings vs Market: IONS's earnings (15.5% per year) are forecast to grow faster than the US market (14.5% per year).
High Growth Earnings: IONS's earnings are forecast to grow, but not significantly.
Revenue vs Market: IONS's revenue (11.2% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: IONS's revenue (11.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IONS's Return on Equity is forecast to be low in 3 years time (3.4%).
Next Steps
Past Performance
How has Ionis Pharmaceuticals performed over the past 5 years?
67.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IONS has high quality earnings.
Growing Profit Margin: IONS became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: IONS has become profitable over the past 5 years, growing earnings by 67.3% per year.
Accelerating Growth: IONS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: IONS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (66.2%).
Return on Equity
High ROE: IONS's Return on Equity (26.8%) is considered high.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Ionis Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: IONS's short term assets ($2.4B) exceed its short term liabilities ($231.8M).
Long Term Liabilities: IONS's short term assets ($2.4B) exceed its long term liabilities ($1.2B).
Debt to Equity History and Analysis
Debt Level: IONS's debt to equity ratio (43.8%) is considered high.
Reducing Debt: IONS's debt to equity ratio has reduced from 48.2% to 43.8% over the past 5 years.
Debt Coverage: IONS's debt is well covered by operating cash flow (27.9%).
Interest Coverage: IONS earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Inventory Level: IONS has a low level of unsold assets or inventory.
Debt Coverage by Assets: IONS's debt is covered by short term assets (assets are 3.7x debt).
Next Steps
Dividend
What is Ionis Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate IONS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate IONS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IONS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IONS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IONS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.6yrs
Average management tenure
CEO
Brett Monia (58yo)
0.08yrs
Tenure
US$4,275,699
Compensation
Dr. Brett P. Monia, Ph.D., is a Founder of Ionis Pharmaceuticals, Inc. and has been its Chief Executive Officer since 2020. Dr. Monia is Chief Operating Officer of Ionis Pharmaceuticals, Inc. since January ...
CEO Compensation Analysis
Compensation vs Market: Brett's total compensation ($USD4.28M) is below average for companies of similar size in the US market ($USD6.26M).
Compensation vs Earnings: Brett's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | 29yrs | US$7.63m | 0.57% $48.1m | |
| Founder | 0.08yrs | US$4.28m | 0.020% $1.7m | |
| Senior VP of Finance & CFO | 7.1yrs | US$2.79m | 0.023% $1.9m | |
| Senior VP of Legal | 7.1yrs | US$2.80m | 0.015% $1.2m | |
| Senior Vice President of Development | 11.5yrs | US$2.97m | 0.021% $1.8m | |
| Senior Strategic Advisor & Director | 19.4yrs | US$6.31m | 0.046% $3.9m | |
| Chief Scientific Officer | 0.08yrs | US$958.87k | 0.023% $1.9m | |
| Vice President of Investor Relations | 7.6yrs | no data | no data | |
| Vice President of Communications | 0yrs | no data | no data | |
| Chief Corporate Development & Commercial Officer | 0.08yrs | no data | no data |
4.6yrs
Average Tenure
61yo
Average Age
Experienced Management: IONS's management team is considered experienced (4.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | 29yrs | US$7.63m | 0.57% $48.1m | |
| Founder | 0.08yrs | US$4.28m | 0.020% $1.7m | |
| Senior Strategic Advisor & Director | 19.4yrs | US$6.31m | 0.046% $3.9m | |
| Director | 14.2yrs | US$635.14k | 0.0091% $768.8k | |
| Director | 26.1yrs | US$662.14k | 0.044% $3.7m | |
| Director | 18.9yrs | US$628.14k | 0.010% $852.6k | |
| Director | 6.7yrs | US$635.14k | 0.011% $912.6k | |
| Director | 17.8yrs | US$663.14k | 0.069% $5.8m | |
| Director | 6yrs | US$643.14k | 0.0095% $800.1k | |
| Director | 1.4yrs | US$1.29m | 0.0013% $106.6k |
16.0yrs
Average Tenure
66.5yo
Average Age
Experienced Board: IONS's board of directors are seasoned and experienced ( 16 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.9%.
Top Shareholders
Company Information
Ionis Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Ionis Pharmaceuticals, Inc.
- Ticker: IONS
- Exchange: NasdaqGS
- Founded: 1989
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$8.458b
- Shares outstanding: 140.66m
- Website: https://www.ionispharma.com
Number of Employees
Location
- Ionis Pharmaceuticals, Inc.
- 2855 Gazelle Court
- Carlsbad
- California
- 92010
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| IONS | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | May 1991 |
| ISI | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | May 1991 |
| IONS | SWX (SIX Swiss Exchange) | Yes | Common Stock | CH | CHF | May 1991 |
| 0JDI | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | May 1991 |
| IONS * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | May 1991 |
Biography
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It is involved in developing neurology products that include IONIS-HTTRx for Huntington’s diseases; and IONIS-SOD1Rx and IONIS-C9Rx for amyotrophic lateral sclerosis and IONIS-MAPTRx for Alzheimer's diseases. The company is also developing severe and rare disease products, such as WAYLIVRA, a treatment for familial chylomicronemia syndrome; WAYLIVRA, a treatment for familial partial lipodystrophy; AKCEA-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; and IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity, IONIS-PKKRx/IONIS-PKK-LRx for hereditary angioedema, and IONIS-ENAC-2.5Rx for cystic fibrosis. In addition, its cardio metabolic and renal drugs include AKCEA-ANGPTL3-LRx for cardio metabolic disorders, IONIS-FXIRx for clotting disorders, AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular diseases, and IONIS-DGAT2Rx for nonalcoholic steatohepatitis; IONIS-AGT-LRX for the treatment of resistant hyper tension; and IONIS-FXI-LRx for clotting disorders and IONIS-AZ4-2.5-LRx for cardiovascular diseases. Further, the company develops products for oncology that include IONIS-AR-2.5Rx and danvatirsen for cancers; and IONIS-HBVRx and IONIS-HBV-LRx for hepatitis b virus infection, and IONIS-FB-LRx for compliment meditated disease, and IONIS-JBI1-2.5Rx for gastrointestinal autoimmune diseases. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/16 23:44 |
| End of Day Share Price | 2020/02/14 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.